Clinical Trial Update: An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease [Phase 2, Phase 3]

View source ↗

Summary

Centocor's Phase 2/Phase 3 efficacy and safety study of an anti-TNF monoclonal antibody for Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Crohn Disease | Phase 2, Phase 3 | Status: COMPLETED